Cargando…

Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo(−/−) mice

In solid tumors, HIF1 upregulates the expression of hundreds of genes involved in cell survival, tumor growth, and adaptation to the hypoxic microenvironment. HIF1 stabilization and activity are suppressed by prolyl and asparagine hydroxylases, which require oxygen as a substrate and ascorbate as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Elizabeth J, Vissers, Margreet CM, Dachs, Gabi U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085285/
https://www.ncbi.nlm.nih.gov/pubmed/27800507
http://dx.doi.org/10.2147/HP.S103088
_version_ 1782463543922130944
author Campbell, Elizabeth J
Vissers, Margreet CM
Dachs, Gabi U
author_facet Campbell, Elizabeth J
Vissers, Margreet CM
Dachs, Gabi U
author_sort Campbell, Elizabeth J
collection PubMed
description In solid tumors, HIF1 upregulates the expression of hundreds of genes involved in cell survival, tumor growth, and adaptation to the hypoxic microenvironment. HIF1 stabilization and activity are suppressed by prolyl and asparagine hydroxylases, which require oxygen as a substrate and ascorbate as a cofactor. This has led us to hypothesize that intracellular ascorbate availability could modify the hypoxic HIF1 response and influence tumor growth. In this study, we investigated the effect of variable intracellular ascorbate levels on HIF1 induction in cancer cells in vitro, and on tumor-take rate and growth in the Gulo(−/−) mouse. These mice depend on dietary ascorbate, and were supplemented with 3,300 mg/L, 330 mg/L, or 33 mg/L ascorbate in their drinking water, resulting in saturating, medium, or low plasma and tissue ascorbate levels, respectively. In Lewis lung carcinoma cells (LL/2) in culture, optimal ascorbate supplementation reduced HIF1 accumulation under physiological but not pathological hypoxia. LL/2, B16-F10 melanoma, or CMT-93 colorectal cancer cells were implanted subcutaneously into Gulo(−/−) mice at a range of cell inocula. Establishment of B16-F10 tumors in mice supplemented with 3,300 mg/L ascorbate required an increased number of cancer cells to initiate tumor growth compared with the number of cells required in mice on suboptimal ascorbate intake. Elevated ascorbate intake was also associated with decreased tumor ascorbate levels and a reduction in HIF1α expression and transcriptional activity. Following initial growth, all CMT-93 tumors regressed spontaneously, but mice supplemented with 33 mg/L ascorbate had lower plasma ascorbate levels and grew larger tumors than optimally supplemented mice. The data from this study indicate that improved ascorbate intake is consistent with increased intracellular ascorbate levels, reduced HIF1 activity and reduced tumor initiation and growth, and this may be advantageous in the management of cancer.
format Online
Article
Text
id pubmed-5085285
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50852852016-10-31 Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo(−/−) mice Campbell, Elizabeth J Vissers, Margreet CM Dachs, Gabi U Hypoxia (Auckl) Original Research In solid tumors, HIF1 upregulates the expression of hundreds of genes involved in cell survival, tumor growth, and adaptation to the hypoxic microenvironment. HIF1 stabilization and activity are suppressed by prolyl and asparagine hydroxylases, which require oxygen as a substrate and ascorbate as a cofactor. This has led us to hypothesize that intracellular ascorbate availability could modify the hypoxic HIF1 response and influence tumor growth. In this study, we investigated the effect of variable intracellular ascorbate levels on HIF1 induction in cancer cells in vitro, and on tumor-take rate and growth in the Gulo(−/−) mouse. These mice depend on dietary ascorbate, and were supplemented with 3,300 mg/L, 330 mg/L, or 33 mg/L ascorbate in their drinking water, resulting in saturating, medium, or low plasma and tissue ascorbate levels, respectively. In Lewis lung carcinoma cells (LL/2) in culture, optimal ascorbate supplementation reduced HIF1 accumulation under physiological but not pathological hypoxia. LL/2, B16-F10 melanoma, or CMT-93 colorectal cancer cells were implanted subcutaneously into Gulo(−/−) mice at a range of cell inocula. Establishment of B16-F10 tumors in mice supplemented with 3,300 mg/L ascorbate required an increased number of cancer cells to initiate tumor growth compared with the number of cells required in mice on suboptimal ascorbate intake. Elevated ascorbate intake was also associated with decreased tumor ascorbate levels and a reduction in HIF1α expression and transcriptional activity. Following initial growth, all CMT-93 tumors regressed spontaneously, but mice supplemented with 33 mg/L ascorbate had lower plasma ascorbate levels and grew larger tumors than optimally supplemented mice. The data from this study indicate that improved ascorbate intake is consistent with increased intracellular ascorbate levels, reduced HIF1 activity and reduced tumor initiation and growth, and this may be advantageous in the management of cancer. Dove Medical Press 2016-04-08 /pmc/articles/PMC5085285/ /pubmed/27800507 http://dx.doi.org/10.2147/HP.S103088 Text en © 2016 Campbell et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Campbell, Elizabeth J
Vissers, Margreet CM
Dachs, Gabi U
Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo(−/−) mice
title Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo(−/−) mice
title_full Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo(−/−) mice
title_fullStr Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo(−/−) mice
title_full_unstemmed Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo(−/−) mice
title_short Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo(−/−) mice
title_sort ascorbate availability affects tumor implantation-take rate and increases tumor rejection in gulo(−/−) mice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085285/
https://www.ncbi.nlm.nih.gov/pubmed/27800507
http://dx.doi.org/10.2147/HP.S103088
work_keys_str_mv AT campbellelizabethj ascorbateavailabilityaffectstumorimplantationtakerateandincreasestumorrejectioningulomice
AT vissersmargreetcm ascorbateavailabilityaffectstumorimplantationtakerateandincreasestumorrejectioningulomice
AT dachsgabiu ascorbateavailabilityaffectstumorimplantationtakerateandincreasestumorrejectioningulomice